Font size
- 1 2 3 + Font size

click to adjust

Page tools
Contact for specific questions
. Advanced search
Product Search
Information on veterinary pharmaceutical products:
For more search options
Recommended Links

International version

Version US

Dosage and Duration of Treatment

Summary: International Baytril Formulations

Baytril is available in three different tablet strengths and as injectable solution. This allows the veterinarian to start treatment with an injection and dispense Baytril tablets to the pet owner for follow-up treatment at home.

In general Baytril is given to cats and dogs at 5 mg/kg b.w. once daily for 5 10 consecutive days.

Recent findings suggest that once daily application of the total daily dose maximises the success of Baytril therapy.
This regimen also offers more convenience to the animal owner and significantly increases therapeutic compliance.   

For more details please consult your local product information.

Summary: US Baytril Formulations

Baytril is available as Baytril Taste TabsTM in different strenghts with flavouring enhancement, and as coated tablets without flavour. An injectable solution is also available. Baytril Otic is a combination of enrofloxacin and silver sulfadiazine registered for the treatment of canine otitis externa complicated by bacterial and fungal organisms.

Baytril tablets are given to dogs at a dose of  5 20 mg/kg b.w., preferably once daily. This gives the veterinarian the possibility to adapt the therapeutic dose within this range to the severity of the disease and susceptibility of the pathogen.
In cats Baytril tablets are dosed at 5 mg/kg b.w., preferably once daily.

Duration of treatment in dogs and cats should be based on clinical evidence. In general administration of Baytril tablets should continue for at least 2 3 days beyond cessation of clinical signs. For severe and complicated infections, more extended intervals of treatment (up to 30 days) may be necessary.

For more details please consult the Bayer Corporation Baytril companion animal website.

Detailed information:

Depending on the local registration in different countries, free choice has been left to the user in the past, to administer the entire daily dose of Baytril once a day (SID), or divide it into two applications (BID).

Recent findings suggest that it is the total dose of enrofloxacin and not the dosing frequency that is significant in determining drug efficacy and therapeutic success (4). It has been concluded that Baytril, like other fluoroquinolones, exhibits concentration-dependent killing activity against Gram-negative and Gram-positive pathogens relevant for small animal practice (4), (5). Maintaining sufficient drug concentrations above the MIC of the pathogen during the entire treatment interval, which is necessary for anti-infectives with time-dependent antibacterial activity (beta-lactams), is of minor importance for the fluoroquinolones (4). Goal of Baytril therapy therefore should be to maximise plasma peak concentrations (Cmax). This can only be achieved when the total daily dose is administered in one single application daily. Additionally, once daily application increases convenience of treatment and therapeutic owner and patient compliance.

Baytril is available as tablets in different concentrations of enrofloxacin, and as injectable solutions. The tablets can be easily split in order to achieve accurate dosing according to the body weight of the individual patient.

The injectable solutions allow the vet practitioner to begin treatment with an injection while dispensing one of the tablet formulations to the animal owner for follow-up treatment at home.

PDF Version (Size: 140 KB)   2001 Bayer AG



Meinen JB, McClure JT, Rosin E: Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Am J Vet Res 56: 1219-1224, 1995.


Wetzstein HG, DeJong A: In vitro bactericidal activity and post antibiotic effect of fluoroquinolones used in veterinary medicine. Suppl Compend Contin Educ Pract Vet 18 (2): 22-29, 1996.

Copyright © Bayer HealthCare AG